top of page
White Structure



October 13th, 2022

Adragos Pharma to acquire Sanofi’s manufacturing site in Kawagoe, Japan

Adragos Pharma, a rapidly growing pharmaceutical Contract Development and Manufacturing Organization (CDMO) based in Munich, Germany, signed definitive agreements with Sanofi K.K. for the acquisition of a pharmaceutical manufacturing site in Kawagoe, close to Tokyo, Japan. Adragos Pharma will also enter into a long-term supply agreement with Sanofi K.K, thereby becoming a strategic partner for Sanofi in the Japanese market. Furthermore, Adragos Pharma will introduce new customers to the manufacturing site from Europe, North America as well as the domestic Japanese market. Their second investment in the region, Adragos Pharma will now rank among the Top 3 largest pure-play CDMOs in Japan.

August 9th, 2021

FSN Capital VI partners with Prange Group to accelerate growth of Adragos Pharma

FSN Capital VI has acquired a majority share in Adragos Pharma Group, a growing B2B contract developer and manufacturer (CDMO) for pharmaceuticals. The current owner, Prange Group, remains invested to support Adragos’ journey towards a leading global position in the highly attractive and well-protected pharmaceutical CDMO market.

bottom of page